title: Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
abstract: This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2005;54[No. RR-8]:1--44). The 2006 recommendations include new and updated information. Principal changes include 1) recommending vaccination of children aged 24-59 months and their household contacts and out-of-home caregivers against influenza; 2) highlighting the importance of administering 2 doses of influenza vaccine for children aged 6 months--<9 years who were previously unvaccinated; 3) advising health-care providers, those planning organized campaigns, and state and local public health agencies to a) develop plans for expanding outreach and infrastructure to vaccinate more persons than the previous year and b) develop contingency plans for the timing and prioritization of administering influenza vaccine, if the supply of vaccine is delayed and/or reduced; 4) reminding providers that they should routinely offer influenza vaccine to patients throughout the influenza season; 5) recommending that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until evidence of susceptibility to these antiviral medications has been re-established among circulating influenza A viruses; and 6) using the 2006-07 trivalent influenza vaccine virus strains: A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. For the A/Wisconsin/67/2005 (H3N2)-like antigen, manufacturers may use the antigenically equivalent A/Hiroshima/52/2005 virus; for the B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus. A link to this report and other information can be accessed at http://www.cdc.gov/flu.
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, GA 30333, USA.
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Smith
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Bresee
authors.forename: David K
authors.initials: DK
authors.lastname: Shay
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Uyeki
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Cox
authors.forename: Raymond A
authors.initials: RA
authors.lastname: Strikas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D007223:Infant; D009980:Influenza A virus; D009981:Influenza B virus; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D008875:Middle Aged; D011310:Preservatives, Pharmaceutical; D013849:Thimerosal; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated
chemical_list: D000998:Antiviral Agents; D007252:Influenza Vaccines; D011310:Preservatives, Pharmaceutical; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D013849:Thimerosal